Large Biotech 13Fs: Amgen, Gilead, Vertex, Regeneron, Biogen

US-traded large biotech equities form a distinctive specialty pharma corner of institutional 13F positioning. Amgen (AMGN, diversified plus emerging emerging post-Horizon Therapeutics acquisition), Gilead Sciences (GILD, HIV plus oncology), Vertex Pharmaceuticals (VRTX, cystic fibrosis monopoly plus emerging emerging pain, kidney, plus type 1 diabetes), Regeneron Pharmaceuticals (REGN, Eylea plus Dupixent partnered with Sanofi), Biogen (BIIB, multiple sclerosis plus emerging emerging Alzheimer's plus emerging emerging Spinraza plus SMA), plus Moderna (MRNA, post-COVID mRNA platform) anchor the cohort. Multi-year emerging cystic fibrosis monopoly, HIV plus emerging emerging oncology pipelines, plus emerging emerging post-COVID Moderna trajectory drive distinctive institutional positioning. Reading large biotech 13F positioning requires understanding the platform framework plus the multi-year pipeline dynamics.

The large biotech business model

Large biotech companies operate four primary economic engines:

1. Cystic fibrosis monopoly. Multi-year emerging Vertex cystic fibrosis (CF) monopoly drives operator economics. Multi-year emerging Trikafta (elexacaftor/tezacaftor/ivacaftor, approved 2019) plus emerging emerging Kalydeco plus emerging emerging Orkambi plus emerging emerging Symdeko plus emerging emerging emerging emerging Casgevy (gene-editing sickle cell, CRISPR Therapeutics partnered) plus emerging emerging emerging emerging Vanzacaftor triple combination emerging plus emerging emerging next-gen CF drug pipeline drive multi-year emerging emerging CF monopoly.
2. HIV plus oncology pipelines. Multi-year emerging HIV plus oncology pipelines drives Gilead operator economics. Multi-year emerging Gilead HIV (Biktarvy, Descovy, Genvoya) plus emerging emerging Yescarta plus Tecartus CAR-T (Kite Pharma) plus emerging emerging Trodelvy ADC plus emerging emerging emerging emerging Yeztugo (lenacapavir long-acting HIV prevention 2025 approval emerging) drive multi-year emerging emerging HIV plus oncology revenue. Multi-year emerging emerging Daniel O'Day CEO leadership.
3. Post-COVID Moderna. Multi-year emerging post-COVID Moderna trajectory drives multi-year emerging operator transformation. Multi-year emerging Moderna mRNA platform plus emerging emerging mRNA-1083 combination flu plus COVID plus emerging emerging RSV mRNA plus emerging emerging CMV mRNA plus emerging emerging norovirus mRNA plus emerging emerging emerging personalized cancer vaccines (Merck partnered) plus emerging emerging emerging emerging Stephane Bancel CEO leadership.
4. Alzheimer's emerging. Multi-year emerging Alzheimer's pipeline emerging drives Biogen plus Eli Lilly plus emerging emerging Eisai (Biogen partnered) operator positioning. Multi-year emerging Biogen Leqembi (Eisai partnered, FDA approved 2023) plus emerging emerging Eli Lilly Kisunla (FDA approved 2024) plus emerging emerging multi-year Alzheimer's amyloid hypothesis revival plus emerging emerging Phase 3 trials drive multi-year emerging emerging Alzheimer's TAM expansion.

Major US-traded large biotech names

Amgen (AMGN)

Diversified General Medicine (osteoporosis Prolia, plus emerging emerging Repatha cholesterol) plus emerging emerging Oncology (Blincyto plus Kyprolis plus emerging emerging Tarlatamab DLL3 BiTE) plus emerging emerging Inflammation (Otezla plus emerging emerging TEZSPIRE Sanofi-AstraZeneca partnered) plus emerging emerging Rare Disease (post-Horizon Therapeutics acquisition 2023) plus emerging emerging Bob Bradway CEO leadership.

Gilead Sciences (GILD)

Diversified HIV plus emerging emerging Oncology (Kite Pharma CAR-T plus Trodelvy ADC plus Tecartus) plus emerging emerging Liver Disease (Sovaldi plus Harvoni plus Vemlidy) plus emerging emerging Daniel O'Day CEO leadership.

Vertex Pharmaceuticals (VRTX)

Diversified Cystic Fibrosis monopoly plus emerging emerging Casgevy (gene-edited sickle cell, CRISPR Therapeutics partnered) plus emerging emerging Suzetrigine non-opioid pain emerging plus emerging emerging Type 1 diabetes Zimislecel emerging plus emerging emerging IgA nephropathy povetacicept emerging plus emerging emerging Reshma Kewalramani CEO leadership.

Regeneron Pharmaceuticals (REGN)

Diversified Eylea (wet AMD) plus emerging emerging Dupixent (Sanofi partnered atopic dermatitis plus asthma plus emerging emerging CRSwNP plus emerging emerging EoE plus emerging emerging COPD plus emerging emerging prurigo nodularis) plus emerging emerging Libtayo PD-1 plus emerging emerging Leonard Schleifer plus George Yancopoulos co-founders.

Biogen (BIIB)

Diversified Multiple Sclerosis (Tysabri plus emerging emerging emerging emerging Vumerity plus Tecfidera generic) plus emerging emerging Alzheimer's (Leqembi Eisai partnered) plus emerging emerging Rare Disease (Spinraza SMA) plus emerging emerging Christopher Viehbacher CEO leadership.

Moderna (MRNA)

mRNA platform plus emerging emerging Spikevax COVID-19 vaccine plus emerging emerging mRESVIA RSV mRNA vaccine (FDA approved 2024) plus emerging emerging mRNA-1083 combination flu plus COVID plus emerging emerging cancer vaccines (Merck partnered) plus emerging emerging Stephane Bancel CEO leadership.

How institutional managers position around large biotech

Three patterns appear across smart-money 13Fs:

Pattern 1: CF-monopoly concentration

VRTX-concentrated growth manager positions reflect cystic fibrosis monopoly plus emerging emerging emerging pipeline diversification thesis.

Pattern 2: HIV-oncology positioning

GILD-concentrated active manager positions reflect HIV plus emerging oncology thesis.

Pattern 3: Alzheimer's positioning

BIIB-concentrated value-discipline manager positions reflect Alzheimer's plus emerging emerging operational restructuring thesis.

How to read large biotech 13F positioning

Three rules apply:

Rule 1: Identify therapeutic area

CF vs HIV vs oncology vs Alzheimer's have distinct dynamics.

Rule 2: Watch pipeline readouts

Multi-year clinical trial readouts drive operator pipeline.

Rule 3: Cross-check patent expiration

Multi-year patent cliff drives revenue dynamics.

What large biotech positioning signals

1. CF-monopoly conviction. Concentrated VRTX positions signal CF monopoly thesis.
2. HIV-oncology conviction. Concentrated GILD positions signal HIV plus oncology thesis.
3. Alzheimer's conviction. Concentrated BIIB positions signal Alzheimer's thesis.

For real-time tracking of large biotech 13F activity, see the institutional signals feed.